The Tolcapone in Parkinson's Disease Study Group II includes the following individuals: Antonie Beiske, Nordbyhagen, Norway; Jean-Marc Burgunder, Bern, Switzerland; Erik Dupont, Arhus, Denmark; Leslie Findley, Romford, U.K.; Richard Godwin-Austen, Nottingham, U.K.; Christian Walter Hess, Bern, Switzerland; Malcolm Home, Melbourne, Australia; Jan Petter Larsen, Stavanger, Norway; Bo Ekstedt, örebro, Sweden; Bent Mikkelsen, Hjörring, Denmark; Jan-Edvin Olsson, Linköping, Sweden; Sven Palhagen, Jönköping, Sweden; Ragnar Palm, Karlstad, Sweden; Ole-Björn Tysnes, Bergen-Haukeland, Norway; Chris van der Linden, Gent, Belgium; and Lene Wermuth, Odense, Denmark.
Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study
Article first published online: 4 NOV 2004
Copyright © 1997 Movement Disorder Society
Volume 12, Issue 6, pages 928–934, November 1997
How to Cite
Dupont, E., Burgunder, J.-M., Findley, L. J., Olsson, J.-E. and Dorflinger, E. (1997), Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study. Mov. Disord., 12: 928–934. doi: 10.1002/mds.870120615
- Issue published online: 4 NOV 2004
- Article first published online: 4 NOV 2004
- Manuscript Revised: 25 FEB 1997
- Manuscript Accepted: 25 FEB 1997
- Manuscript Received: 3 SEP 1996
- Parkinson's disease;
- Wearing-off phenomenon;
- Motor fluctuations;
The primary objective of this study was to assess the effect of tolcapone on levodopa dosage in parkinsonian patients whose “wearing-off” phenomenon has been controlled with more frequent levodopa dosage. After a 1-week placebo run-in, 97 patients were assigned randomly to receive placebo or tolcapone 200 or 400 mg three times daily (t.i.d.). Levodopa dosage was reduced by −35% on day 1 of study and subsequently retitrated as required. After 6 weeks, the tolcapone groups crossed over to receive the other dose for a further 3 weeks for exploratory purposes. Both tolcapone groups had greater reductions in levodopa dosage than the placebo group at week 6 (not statistically different). The 200-mg t.i.d. group showed greatest improvement in estimated mean scores for all efficacy parameters (p < 0.05 versus placebo for change in Unified Parkinson's Disease Rating Scale Subscale II). Fewer dopaminergic and nondopaminergic adverse events were associated with tolcapone 200 mg t.i.d. than with tolcapone 400 mg t.i.d. The most frequently reported dopaminergic adverse events were nausea, cramps, dyskinesia, and dystonia. The most frequently reported unanticipated adverse event was diarrhea. Tolcapone 200 mg t.i.d. may provide additional benefit to patients with moderately advanced Parkinson's disease with treated “wearing-off” phenomenon.